A B S T R A C T
A B S T R A C T The anti-helminthic drug levamisole hydrochloride has been reported to stimulate immune responses in humans and experimental animals. We have investigated levamisole effects on human leukocyte locomotion in vitro in studies of neutrophils and mononuclear cells from normal adults, from patients with Chediak-Higashi disease and from patients with the syndrome of hyperimmunoglobulin E, recurrent pyogenic infections, and defective leukocyte chemotaxis. Directed migration (chemotaxis) of neutrophils and mononuclear cells from normal adults and from the hyperimmunoglobulin E syndrome patients, but not from Chediak-Higashi patients, were stimulated by levamisole at concentrations of 0.01-1.0 ,uM, with stimulation observed most consistently at 0.1 /.LM. These concentrations of drug also increased cyclic GMP levels in mononuclear cells and enhanced hexose monophosphate shunt activity in neutrophils, but did not alter chemotactic factor-induced changes in the surface charge of neutrophils. Other concentrations of levamisole did not affect leukocyte locomotion except for a high concentration (5.0 mM) which stimulated both random and directed leukocyte migration.
When patients with the hyperimmunoglobulin E syndrome took levamisole by mouth, the abnormal chemotactic responses of their neutrophils were significantly improved towards normal. These studies are the first to show pharmacologic improvement of in vitro leukocyte locomotion in patients in whom recurrent infections have been attributed to a defect of this leukocyte function. INTRODUCTION Levamisole hydrochloride has been used widely in veterinary and in human medicine as an anti-helminthic, particularly for nematode infections (1) (2) (3) . However, there has been recent interest in possible effects of this drug on immune responses and in immune deficiency. Various functions of lymphocytes and of phagocytic cells have been reported to be enhanced by levamisole (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) and these findings have encouraged the trial of this drug in patients with suspected host defense defects (14) (15) (16) .
While directed migration of leukocytes (chemotaxis) has long been thought to be important in immune responses, reproducible techniques for measuring this leukocyte function in vitro are recent developments (17) . Reports of abnormal leukocyte chemotaxis in patients with syndromes of recurrent infections are also recent (18) .
In these studies we have investigated the effects of levamisole on the locomotion of human neutrophils and mononuclear cells from normal adults and from patients with syndromes characterized by defective leukocyte chemotaxis and recurrent bacterial infections. These studies show that levamisole increases the chemotactic responses of both normal and abnormal leukocytes at concentrations which may be achieved in vivo after oral administration.
METHODS

Human subjects
Healthy adults of both sexes donated blood from which leukocytes were obtained to define nonnal leukocyte function with and without levamisole. aged 21 and 25 yr, with Chediak-Higashi (C-H)l disease, both of whom have been described in previous clinical reports (19) . The chemotactic responses of their neutrophils (20) and mononuclear cells (21) have been shown to be markedly impaired. Both patients have had recurrent pyogenic infections throughout their lives. In addition, four patients with recurrent pyogenic infections and consistently elevated levels of serum IgE were studied. Abnormal neutrophil and mononuclear cell chemotaxis have been found consistently in these patients during follow-up at the National Institutes of Health for 9 mo to 5 yr. Two patients (patient D [22, 23] and patient B [24] , Table I ) have been subjects of case reports in which these abnormalities were described. Each of these patients has suffered from bacterial abscesses and pneumonias requiring multiple drainage procedures. Lymphocytes from these patients have shown impaired transformation responses to antigens in vitro as reported by others in comparable patients (25) . Clinical features of these four patients are summarized in Table I . The syndrome, represented by these patients and described by several authors, lacks a generally recognized eponym (reviewed in 25) , and for convenience, we have used the term hyperimmunoglobulin E (HIE) syndrome in referring to these patients.
Levamisole
Levamisole hydrochloride, the levo-rotatory enantiomere of tetramisole, was obtained from Janssen R and D, New Brunswick, N. J. The purity of this synthetic compound (mol wt 240.75; lot no. SM17311) was determined by the manufacturer to be greater than 99% with spectrophotometric methods. For in vitro studies, the drug was dissolved in ' Abbreviations used in this paper: cAMP, cyclic adenosine monophosphate; cGMP, cyclic guanosine monophosphate; C-H, Chediak-Higashi; HIE, hyperimmunoglobulin E. 0.85% saline to appropriate concentrations immediately before use. Leukocytes were exposed in vitro to levamisole or to saline alone in media that contained no more than 10%o levamisole solution or saline.
For certain studies, patients were given levamisole by mouth. Levamisole tablets used in these studies contained 50 mg levamisole HCI, 42 
Measurement of leukocyte migration
Neutrophils. Neutrophil directed migration (chemotaxis) and random migration were measured in vitro with a radioassay that employs 5'Cr-labeled neutrophils and double micropore filter chemotactic chambers (26) , and with a morphologic assay in which the distance migrated into a micropore filter is assessed (27) (29) . In these studies, two chemotactic stimuli were used: endotoxin activated serum (fresh normal serum incubated with Escherichia coli lipopolysaccharide B 0127:B8, Difco Laboratories, Detroit, Mich. (30) and casein (sodium caseinate, Difco Laboratories). Activated serum preparations contained 2.5% serum in the final stimulus solutions; casein solutions contained 5 mg/ml sodium caseinate in 0.85% saline.
Mononuclear cells. Mononuclear cell migration was tested by means of a previously described morphologic assay (31) . Human mononuclear cells were separated from heparinized blood by use of Hypaque-Ficoll gradients and suspended in Gey's medium at a concentration of 2.3 x 106 cells/ml. The same chemotactic chambers used to measure neutrophil migration were used in this assay except that a single 5-im pore polycarbonate filter (Neuro Probe, Inc. Bethesda, Md.) separated the two chamber compartments. Endotoxin-activated normal serum was used as the chemotactic stimulus. Experimental conditions for spontaneous random migration, activated random migration, and directed migration were again compared. After incubation of cells and stimuli for 90 min at 37°C in 100%o humidity and 5% CO2, the filters were removed, fixed, and stained. Cells that had migrated to the undersides of the filters were counted in five separate high power fields (21 
Measurement of cellular cyclic nucleotides
Cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP) levels in neutrophils and in mononuclear cells were measured by radioimmunoassay as described previously (33, 34) . Preparations of neutrophils and mononuclear cells were obtained as described above. Preliminary experiments showed that no effects of levamisole on cyclic nucleotide accumulation were detectable unless the cells were incubated in the presence of imidazole (0.01 ,uM). Imidazole by itself did not significantly raise cyclic nucleotide levels in the absence of other stimuli. In the experiments reported here, cells were preincubated for 15 min at 37°C in media with 0.01 ,iM imidazole (Sigma Chemical Co., St. Louis, Mo.). The requirement for imidazole in test conditions for measurable recoveries of cyclic nucleotides has been noted by others (8) . Test substances were then added to the leukocytes, and the incubation was continued for an additional 5 min. The reaction was stopped by the addition of cold 10%o HC104, and the cells were homogenized and the resulting lysates neutralized with KOH. The extracts were applied to columns of Bio-Rad AG-1X8 formate (Bio-Rad Laboratories, Richmond, Calif.) which were then washed with 0.1 N formic acid. cAMP was eluted with 2 N formic acid and cGMP was eluted with 4 N formic acid. After lyophilization to remove formic acid, the cyclic nucleotides were radioimmunoassayed with commercial reagents (Collaborative Research, Waltham, Mass. (Table II , Section C) as well as spontaneous random migration (data not shown). However, levamisole did not possess intrinsic chemotactic activity at any concentration; that is, when drug was present in the stimulus compartment of the chemotactic chambers, migration of cells was not greater than that observed when drug was in the cell compartment or in both compartments of the chambers.
Stimulation of the directed migration of normal and HIE neutrophils by the lower concentrations of levamisole (i.e., 0.1 uM) was found to reflect an effect of the drug on all cells rather than on a select subpopulation. When cells were counted at different depths of cellulose nitrate filters after 45 min of migration, it was found not only that the leading front of levamisole-treated cells had migrated farther than had the untreated cells, but also that the majority of cells exposed to levamisole had traveled farther than the untreated cells. This finding is illustrated by a study with normal neutrophils shown in Fig. 1 . By integrating the migration/cell density curves shown in Fig. 1 , it was possible to determine the median distance migrated by the neutrophils (indicated by the shaded and the nonshaded portions of the curves Random and directed migration of mononuclear cells from patients and normal volunteers. As was found with neutrophils, the directed migration of mononuclear cells from patients with the HIE syndrome and with C-H disease was significantly less than normal (P < 0.05; Table III, Section A). Unlike neutrophils, significant abnormalities of the random migration of patients' mononuclear cells were not evident, although individual studies suggested that such abnormalities might be present.
Effects of levamisole on mononuclear cell migration in vitro. Enhanced directed migration (chemotaxis) of mononuclear cells from both normal donors and HIE patients was observed when cells were exposed to levamisole at 0.01-1.0 M and at 5.0 mM. Although these results were not consistent in every experiment with 0.01-,uM, 1.0-,uM, and 5.0-mM doses, levamisole at 0. 1 Levamisole and Leukocyte Locomotion Effects of levamisole on neutrophil oxidative metabolism. Studies were undertaken to find if levamisole effects on neutrophil migration could be associated with increased hexose monophosphate shunt activity as has been observed with ascorbic acid (36) . As shown in Fig. 2 , low concentrations of the drug (in the range of 0.1 gM) significantly stimulated oxidative metabolism in both resting and phagocytizing cells. In contrast, high concentrations of drug (5.0 mM) did not enhance but rather inhibited oxidative metabolism.
Effects of levamisole on cyclic nucleotide levels in leukocytes. Because serotonin and ascorbic acid stimulate leukocyte chemotactic responsiveness at concentrations that also raise intracellular cGMP in mononuclear cells (34), we studied the effects of levamisole upon cyclic nucleotide levels in normal leukocytes at concentrations of drug that affect locomotion. Levamisole was not found to alter cAMP levels in either neutrophils or mononuclear cells in any consistent way at any concentration. In neutrophils exposed to levamisole, 0.01-1.0 ,uM, elevations in cGMP levels were observed, but these changes were of small magnitude and not statistically significant. However, significant elevations of cGMP were observed in mononuclear cells that had been exposed to levamisole. In the three experiments illustrated in Fig. 3 , one mononuclear cell preparation (A), which showed a marked rise of intracellular cGMP in response to serotonin (0.1 mM), also showed significant increases in cGMP when incubated with levamisole at concentrations of 0.01-1.0 uM. Cell preparations B and C, which responded less to serotonin, also showed significant increases in cGMP with levamisole but only at a 
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D. G. Wright, C. H. Kirkpatrick, and J. I. Gallin concentration of 0.1 ,uM. Since these mononuclear cell preparations contained both monocytes and lymphocytes, we did further studies of levamisole effects on adherent and nonadherent cells separated from mixed mononuclear cell preparations. For these experiments, mononuclear cells were isolated from blood in the usual way and then incubated in Hank's medium (with 10% fetal calf serum) for 24 h in plastic Petri dishes. After incubation, nonadherent cells were washed from the dishes. Adherent cells were detached from the plates with a rubber policeman (34) . Both adherent and nonadherent cell populations showed increases in cGMP in response to 0.1 ,uM levamisole. Effects of levamisole on neutrophil surface charge. The chemotactic factors C5a, kallikrein, plasminogen activator, and dialyzable transfer factor have been shown to decrease neutrophil surface charge (35) . One agent that inhibited leukocyte chemotaxis, hydrocortisone sodium succinate, prevented the C5a-induced changes in neutrophil surface charge suggesting an effect of this drug at the cell surface (35) . To evaluate the possibility that the enhanced migration noted with levamisole was associated with cell surface events, we studied the electrophoretic mobility of neutrophils exposed to levamisole with a C5a. As shown in Table IV levamisole and C1, respectively; these differences were significant, P < 0.01, by paired sample t test). Furthermore, additional improvement in neutrophil directed migration was noted after these patients took the second course of drug, although the changes were not as great as after the first course. Neutrophil responses to buffer alone, reflecting spontaneous random migration of the cells, were not significantly different before and after the courses of levamisole. The results shown in Fig. 4 , which were obtained by the radioassay of neutrophil migration, were confirmed in studies using the morphologic "leading front" assay. DISCUSSION Various agents (ascorbic acid, serotonin, and carbachol) have been shown to stimulate leukocyte locomotion in vitro (34, 36) . The studies presented in this report, however, are the first to demonstrate pharmacologic improvement of the in vitro migration responses of leukocytes from patients in whom recurrent infection has been attributed to a defect in this leukocyte function (37) . Levamisole at concentrations in vitro (0.1 ,uM) that are compatible with blood levels observed after oral administration (38) was found to significantly improve the deficient migration responses of neutrophils and mononuclear cells from four patients with recurrent pyogenic infections and HIE. Neutrophils from these patients also showed improved migration responses after exposure to levamisole in vivo.
Comparable concentrations of levamisole also stimulated migration responses of leukocytes from normal individuals but failed to alter the abnormal directed and random migration of leukocytes of patients with the C-H syndrome.
In a recently reported study (39) , (-) tetramisole (levamisole) was shown to enhance normal monocyte chemotaxis at high doses (1.0 mM). We also found significant stimulation of normal monocyte chemotaxis at comparable doses in individual experiments but could not show this effect to be consistent. However, we did find that high concentrations of levamisole (1.0 mM and above) enhanced neutrophil locomotion, although in an apparently different manner than observed with the effective lower concentrations (0.01-1.0 uM). The lower concentrations of drug raised leukocyte cGMP levels and stimulated oxidative metabolism in neutrophils; the high concentrations lacked these effects.
The in vitro techniques used in these studies to assess leukocyte chemotaxis necessarily measure several coordinated cellular events, including cell locomotion per se, the sensitivity of cells to a chemotactic factor, and the orientation of cells in response to a gradient of a chemotactic factor. However, by comparing the experimental conditions of directed migration, activated random migration, and spontaneous random migration, it is possible to gain some insight into the manner in which levamisole stimulates leukocyte chemotaxis. At high concentrations of drug (5.0 mM), all forms of leukocyte migration were stimulated, and thus the drug at this concentration appears to affect cell locomotion per se. In contrast, the effective lower concentrations (0.01-1.0 ,M) were found to stimulate only directed migration and activated random migration, and thus appear to enhance the responsiveness of leukocytes to chemotactic factors and not simply to stimulate cell locomotion per se. The apparent increased sensitivity to chemotactic factors was not, however, reflected by changes in the effects of chemotactic factors upon cell surface charge. This increase in the responsiveness of leukocytes to a chemotactic factor may result from an increased ability of the cells to sense the chemotactic substance and (or) from an increase in the ability of cells to orient themselves. The methods used are unable to distinguish these effects. Our laboratory has recently described a technique of evaluating leukocyte orientation per se (40) , and it will be appropriate to reexamine the effects of levamisole on leukocyte migration with such techniques.
By comparing the conditions of random and directed migration, it is also possible to gain some insight into the character of the locomotion abnormalities of C-H and HIE leukocytes. The Levamisole has been used empirically as treatment for a variety of diseases other than helminthic infections. Of particular relevance to the present studies is a report of apparent clinical improvement with levamisole therapy in a child with recurrent pyogenic infections, HIE, and mucocutaneous candidiasis (14) . However, it is to be emphasized that our studies of leukocyte function in vitro do not show that levamisole will prove to be clinically useful to patients with recurrent infection. Although it may be theoretically attractive to associate recurrent infections with abnormalities of leukocyte locomotion, it cannot be assumed that pharmacologic improvement of this in vitro cell function will lead to clinical benefits. Pursuit of the question of clinical usefulness of levamisole in certain individuals, such as those with HIE syndrome, will require appropriately controlled clinical trials.
Note added in proof. Since submission of this paper, two reports have been published that describe findings similar in part to our own (41, 42) .
